from their site:
Rumsfeld's growing stake in Tamiflu
Defense Secretary, ex-chairman of flu treatment rights holder, sees portfolio value growing.
October 31, 2005: 10:55 AM EST
By Nelson D. Schwartz, Fortune senior writer
Crain's Cleveland Business
Bob Schmidt, the outspoken entrepreneur and president of Cleveland Medical...
www.crainscleveland.com
SuperArray.com - Biotechnology Company
SuperArray Bioscience Corporation is a privately held biotechnology company....
www.superarray.com
Biotechnology Filtration Production
We support our customers in all bioprocess steps, ranging from active ingredient...
www.sartorius.com
National Biotech Register Online
A complete list of biotech companies. Free access. Search by company or keyword....
www.biotech-register.com
NEW YORK (Fortune) - The prospect of a bird flu outbreak may be panicking people around the globe, but it's proving to be very good news for Defense Secretary Donald Rumsfeld and other politically connected investors in Gilead Sciences, the California biotech company that owns the rights to Tamiflu, the influenza remedy that's now the most-sought after drug in the world.
Rumsfeld served as Gilead (Research)'s chairman from 1997 until he joined the Bush administration in 2001, and he still holds a Gilead stake valued at between $5 million and $25 million, according to federal financial disclosures filed by Rumsfeld.
The forms don't reveal the exact number of shares Rumsfeld owns, but in the past six months fears of a pandemic and the ensuing scramble for Tamiflu have sent Gilead's stock from $35 to $47. That's made the Pentagon chief, already one of the wealthiest members of the Bush cabinet, at least $1 million richer.
Rumsfeld isn't the only political heavyweight benefiting from demand for Tamiflu, which is manufactured and marketed by Swiss pharma giant Roche. (Gilead receives a royalty from Roche equaling about 10% of sales.) Former Secretary of State George Shultz, who is on Gilead's board, has sold more than $7 million worth of Gilead since the beginning of 2005.
"I don't know of any biotech company that's so politically well-connected," says analyst Andrew McDonald of Think Equity Partners in San Francisco.
What's more, the federal government is emerging as one of the world's biggest customers for Tamiflu. In July, the Pentagon ordered $58 million worth of the treatment for U.S. troops around the world, and Congress is considering a multi-billion dollar purchase. Roche expects 2005 sales for Tamiflu to be about $1 billion, compared with $258 million in 2004.
More at link:
http://money.cnn.com/2005/10/31/news/newsmakers/fortune_rumsfeld/--------------------------
EDIT: COPYRIGHT. PLEASE POST ONLY FOUR OR FIVE
PARAGRAPHS FROM THE COPYRIGHTED NEWS SOURCE
PER DU RULES.